跳至主要内容

Medicilon’s Yeast Two Hybrid Services

 The yeast “two hybrid” or “interaction trap” assay, is a technique used to study protein-protein interactions, which are critical in virtually all cellular processes. The study of protein-protein interactions can be divided into three major parts:

• Identification of binding proteins
• Characterization of known interactions
• Potential to manipulate such interactions

yeast 2 hybrid serviceThis technology is based on the fact that the activating domain (AD) and binding domain (BD) of a transcription factor can be separated and still function when they get into close proximity. Y2H screening is therefore designed to use a BD fused bait protein to screen against a library of AD fused prey proteins. The bait is usually a known protein that the researcher tries to identify new interacting partners with. The prey is usually a library of proteins to be screened from. When the bait protein binds to the prey protein, transcription of the specially designed reporter genes occurs and allows selection of this positive clone. Medicilon use modified yeast strains which incorporates several reporter genes to reduce false positives. We also use different GAL4 binding elements to increase sensitivity of the assay.

Yeast Two-Hybrid Procedure

1. Generate a GAL4 DNA-BD fusion by cloning the gene of interest in frame with the GAL4 DNA binding domain of pGBKT7.
2. Transform AH109 with bait plasmid, detect bait expression and test for autoactivation and cell toxicity.
3. Mate the pretransformed library strain with the bait strain.
4. Restreak colonies that can grow on TDO plates to QDO plates.
5. Restreak positive clones to single colonies on QDO/+X-a-Gal plates.
6. Rescue plasmid DNA from positive yeast clones.
7. Identify and isolate AD/library plasmids from E. coli transformants.
8. Cotransform DNA-BD/bait and AD/library plasmids into AH109.
9. Repeat Step 5.

10. Select true positive clones and sequence cDNA inserts.

Our Advantages:

  • Highly reduced rate of false positives
  • Short turn-around time
  • Best price in the market
  • Highly customized service

Medicilon offers a wide range of ready-to-use prey protein cDNA libraries. We can also custom develop homogenized cDNA libraries according to your specific requirements. Screening and validation process can be done in as short as two months! We also provide co-immunoprecipitation service to validate your result from the Y2H screening.

Tips for Two-Hybrid Screening
Minimizing False Positives:
Run replicates of the experiment to reduce the likelihood of indiscriminate reporter gene activation. Including a prey-only control also provides a baseline level of reporter activation.

Vary the expression levels of bait and prey proteins – overexpression can lead to false interactions. Lowered expression levels will increase the stringency of your binding.

And most importantly: Independently validate identified binding partners with other techniques!

 

Minimizing False Negatives:

Interactions leading to detectable reporter signals depend on a number of factors, including protein expression and correct folding, post-translational modification, protein degradation, access to the nucleus in eukaryotic screens and fusion configuration. The possibility for problems with one or more of these parameters can lead to a high number of false negatives in Y2H screens.

Testing your reporter system with a pair of proteins that are known to bind serves as a good positive control to ensure that your setup works. The last thing you want is to run your lovely library screen only to find the system itself is not working because your reporter protein doesn’t function in yeast!

Many false negatives stem from or are exacerbated by expression of target proteins in heterologous systems .

While this may be difficult to resolve for a wide range of prey proteins, there are now a number of two-hybrid systems available in model organisms, including bacteria, alternative fungi and mammalian cells.

If the problem is that your proteins are not post-translationally modified, co-expression of the enzyme responsible for the modification in the assay host strain can help.

In order to reduce the chance that the configuration of your fusion proteins physically blocks the binding sites for the protein partner or the UAS/reporter gene, the same bait and prey libraries can be screened using both N- and C-terminal fusions of these proteins. This way both ‘ends’ of your protein are screened for binding.

Using a variety of expression levels and systems can alleviate false negatives that arise from low or faulty expression of your target proteins. In fact, a good overall strategy to reduce false negatives and produce a more vigourous screen is to use a number of different bait and prey vectors. This has been shown to be as effective as using five independent protein interaction detection methods.

In order to bind DNA and activate a reporter gene in eukaryotic cells, fusion proteins must gain access to the nucleus. To circumvent this requirement for transmembrane proteins, a split ubiquitin system has been devised.

the yeast two-hybrid(Y2H) system

Contact Us

Email : marketing@medicilon.com

Tel : +86 021 58591500

Tips : Above is part of yeast two hybrid analysis, yeast 2 hybrid service and yeast two hybrid screen. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...